drugset / Trial / NCT04154033

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033

Phase 2 Withdrawn University of Minnesota
RandomizedCrossoverQuadruple-blindTreatment

Summary

To study the etiology and the epigenetic pathways leading to and regulating chronic itch. Similarly, to examine the mechanisms underlying skin changes, including epigenetic alterations while also testing the efficacy of medications, especially topical intervention. In this study, the investigators aim to examine chronic sensory disorder mechanisms related to chronic itch.

Timeline

Start
2020-10-01
Primary completion
2024-03-31
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 1 % Topical

Indications